NICOTINAMIDE ( DrugBank: Nicotinamide )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 4 |
| 49 | Systemic lupus erythematosus | 1 |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05589766 (ClinicalTrials.gov) | November 28, 2022 | 13/10/2022 | N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease | N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease | Parkinson Disease | Dietary Supplement: Nicotinamide Riboside;Other: Placebo | Haukeland University Hospital | NULL | Recruiting | 40 Months | 100 Years | All | 80 | N/A | Norway |
| 2 | NCT03568968 (ClinicalTrials.gov) | May 15, 2020 | 14/6/2018 | A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease | A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study | Parkinson Disease | Dietary Supplement: Nicotinamide Riboside;Drug: Placebo | Haukeland University Hospital | NULL | Recruiting | 18 Years | N/A | All | 400 | N/A | Norway |
| 3 | NCT03816020 (ClinicalTrials.gov) | March 9, 2019 | 7/12/2018 | NAD-supplementation in Drug naïve Parkinson's Disease | NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease | Parkinson Disease;Neurodegenerative Diseases | Dietary Supplement: Nicotinamide Riboside;Other: Placebo | Haukeland University Hospital | NULL | Completed | 18 Years | N/A | All | 30 | N/A | Norway |
| 4 | EUCTR2004-005034-39-GB (EUCTR) | 17/05/2005 | 20/04/2005 | Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease | Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease | Idiopathic Parkinson's disease | Trade Name: Nicotinamide Product Name: NICOTINAMIDE INN or Proposed INN: Nicotinamide | Queen Elizabeth Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | United Kingdom |
49. Systemic lupus erythematosus
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03260166 (ClinicalTrials.gov) | August 31, 2017 | 10/8/2017 | Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus | An Open-label Study for Assessing the Efficacy and Safety of Nicotinamide Treatment for Lupus-associated Skin Lesions in Patients With Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus | Cutaneous Lupus Erythematosus;Systemic Lupus Erythematosus Rash | Drug: nicotinamide | Second Xiangya Hospital of Central South University | National Natural Science Foundation of China;Hunan Provincial Natural Science Foundation of China;National Key Clinical Specialty Construction Project of China | Active, not recruiting | 18 Years | 65 Years | All | 40 | Phase 2 | China |